Requires the FDA to issue a rule replacing references to animal testing with nonclinical testing in federal drug and device regulations, and makes the rule take effect immediately.

• Requires HHS, acting through the FDA Commissioner, to publish an interim final rule within one year of enactment.
• Replaces references to "animal" tests, data, studies, models, and research with "nonclinical" in listed sections of Title 21 of the Code of Federal Regulations.
• Adds a definition of "nonclinical test" from section 505(z) of the Federal Food, Drug, and Cosmetic Act to four CFR sections covering investigational drugs, new drug applications, and biologics.
• Makes the interim final rule effective immediately without the agency having to show good cause.
• Redesignates the second subsection (z), on clinical trial diversity action plans, as subsection (aa).

• Energy and Commerce Committee (House)
• Health Subcommittee

Health